MXPA05012101A - Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. - Google Patents
Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.Info
- Publication number
- MXPA05012101A MXPA05012101A MXPA05012101A MXPA05012101A MXPA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A
- Authority
- MX
- Mexico
- Prior art keywords
- binding pocket
- hepatitis
- ns5b polymerase
- polymerase inhibitor
- hcv ns5b
- Prior art date
Links
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 title abstract 4
- 229940123066 Polymerase inhibitor Drugs 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 238000012790 confirmation Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La polimerasa NS5B del HCV, cuando se compleja con ciertos inhibidores, adopta una conformacion en la que la region del bucle de dedo definida por los residuos aminoacidos 18 a 35 esta desplazada para exponer un bolsillo de union generalmente definido por los residuos de aminoacidos 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 y 503. Este bolsillo de union recientemente expuesto define una nueva diana en la busqueda de entidades quimicas adicionales que son capaces de unirse a NS5B del HCV y de modular, o preferiblemente inhibir, la actividad de polimerasa NS5B del HCV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46960403P | 2003-05-09 | 2003-05-09 | |
PCT/CA2004/000676 WO2004099241A1 (en) | 2003-05-09 | 2004-05-05 | Hepatitis c virus ns5b polymerase inhibitor binding pocket |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05012101A true MXPA05012101A (es) | 2006-02-08 |
Family
ID=33435247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05012101A MXPA05012101A (es) | 2003-05-09 | 2004-05-05 | Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. |
Country Status (12)
Country | Link |
---|---|
US (1) | US7386398B2 (es) |
EP (1) | EP1625154B1 (es) |
JP (1) | JP4584909B2 (es) |
KR (1) | KR101164070B1 (es) |
CN (1) | CN100457776C (es) |
AU (1) | AU2004235848B2 (es) |
CA (1) | CA2522574C (es) |
DK (1) | DK1625154T3 (es) |
ES (1) | ES2456702T3 (es) |
IL (1) | IL171800A (es) |
MX (1) | MXPA05012101A (es) |
WO (1) | WO2004099241A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012288A1 (en) | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc | Bicyclic imidazol derivatives against flaviviridae |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8535334B2 (en) * | 2007-04-17 | 2013-09-17 | Lazarus Effect, Inc. | Complex wire formed devices |
US20100286131A1 (en) * | 2007-08-03 | 2010-11-11 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CA2693997C (en) | 2007-08-03 | 2013-01-15 | Pierre L. Beaulieu | Viral polymerase inhibitors |
WO2009033183A2 (en) * | 2007-09-08 | 2009-03-12 | University Of Florida Research Foundation | Compounds and methods for treatment of hcv and conditions associated with cd81 binding |
BRPI0703586B1 (pt) * | 2007-10-19 | 2018-02-06 | Braskem S.A | Catalisador metaloceno suportado, e, copolímeros de etileno com alfa-olefinas de alto e ultra alto peso molecular |
US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
BRPI0922364A2 (pt) * | 2008-12-03 | 2017-08-29 | Presidio Pharmaceuticals Inc | Composto, composição farmacêutica e uso de um composto |
WO2010081149A1 (en) * | 2009-01-12 | 2010-07-15 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
EP2398474A4 (en) * | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
BRPI1009034A2 (pt) * | 2009-06-30 | 2019-09-24 | Siga Tech Inc | composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma |
US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
US20110053892A1 (en) * | 2009-08-31 | 2011-03-03 | Martin Leivers | Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections |
US20110065782A1 (en) * | 2009-09-15 | 2011-03-17 | Malliavin Therese | Methods of identifying compounds that inhibit the activation of a biomolecule and methods of treatment using the compounds |
TW201138786A (en) * | 2010-02-19 | 2011-11-16 | Glaxo Group Ltd | Therapeutic compounds |
US20130296311A1 (en) * | 2010-05-28 | 2013-11-07 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
WO2012040389A2 (en) | 2010-09-22 | 2012-03-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
BR112013009789A2 (pt) | 2010-10-26 | 2016-07-19 | Presidio Pharmaceuticals Inc | inibidores do vírus da hepatite c |
WO2012059413A1 (en) * | 2010-11-02 | 2012-05-10 | Probiodrug Ag | Crystal structure of isoglutaminyl cyclase |
SI2640719T1 (sl) | 2010-11-17 | 2017-07-31 | Gilead Pharmasset Llc | Antivirusne spojine |
WO2012083059A1 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
JP6041877B2 (ja) * | 2011-08-12 | 2016-12-14 | サザン リサーチ インスティテュート | キナゾリノン類似体及び特定のウイルス感染症の治療又は予防へのキナゾリノン類似体の使用 |
PL2907816T3 (pl) | 2011-11-16 | 2019-03-29 | Gilead Pharmasset Llc | Skondensowane imidazolyloimidazole jako związki przeciwwirusowe |
CN108409820A (zh) | 2011-12-20 | 2018-08-17 | 里博科学有限责任公司 | 作为hcv rna复制抑制剂的4′-叠氮基,3′-氟取代的核苷衍生物 |
US20150087045A1 (en) * | 2012-01-13 | 2015-03-26 | Gilead Pharmassset Llc | Crystal structure of hcv polymerase complexes and methods of use |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
US9167288B2 (en) | 2013-03-15 | 2015-10-20 | Universal Electronics Inc. | System and method for optimizing memory usage in a universal controlling device |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
US9895442B2 (en) * | 2013-05-16 | 2018-02-20 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
EP2996696A4 (en) | 2013-05-16 | 2016-12-21 | Riboscience Llc | 4'-AZIDO, 3'-DEOXY-3'-FLUOR-SUBSTITUTED NUCLEOSIDE DERIVATIVES |
CN105579046A (zh) | 2013-08-26 | 2016-05-11 | 英安塔制药有限公司 | 用于预防或治疗丙型肝炎的环孢菌素类似物 |
PL3650014T3 (pl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Preparat złożony dwóch związków przeciwwirusowych |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
WO2016033164A1 (en) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
WO2016073480A1 (en) | 2014-11-03 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Novel cyclosporin analogues for preventing or treating hepatitis c infection |
US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CN104530189B (zh) * | 2014-12-16 | 2017-11-14 | 郑州大学第一附属医院 | 丙型肝炎病毒ns5b rna聚合酶抑制多肽序列及其用途 |
CN111194217B (zh) | 2017-09-21 | 2024-01-12 | 里伯赛恩斯有限责任公司 | 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物 |
WO2023172635A1 (en) * | 2022-03-08 | 2023-09-14 | Emory University | Predictive model for variants associated with drug resistance and theranostic applications thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5528559A (en) * | 1995-06-23 | 1996-06-18 | Motorola, Inc. | Multiple display timepiece |
WO1999057253A2 (en) * | 1998-05-04 | 1999-11-11 | Vertex Pharmaceuticals Incorporated | Crystallizable jnk complexes |
US6434489B1 (en) * | 2000-04-03 | 2002-08-13 | Schering Corporation | Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP1256628A3 (en) * | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
JP4558314B2 (ja) * | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
CA2459890A1 (en) * | 2001-09-06 | 2003-03-20 | Biogen Idec Ma Inc. | Crystal structure of baff, and use thereof in drug design |
US7223785B2 (en) * | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
-
2004
- 2004-05-05 ES ES04731118.8T patent/ES2456702T3/es not_active Expired - Lifetime
- 2004-05-05 EP EP04731118.8A patent/EP1625154B1/en not_active Expired - Lifetime
- 2004-05-05 CA CA2522574A patent/CA2522574C/en not_active Expired - Fee Related
- 2004-05-05 WO PCT/CA2004/000676 patent/WO2004099241A1/en active Application Filing
- 2004-05-05 KR KR1020057021262A patent/KR101164070B1/ko not_active IP Right Cessation
- 2004-05-05 DK DK04731118.8T patent/DK1625154T3/da active
- 2004-05-05 MX MXPA05012101A patent/MXPA05012101A/es active IP Right Grant
- 2004-05-05 JP JP2006500449A patent/JP4584909B2/ja not_active Expired - Fee Related
- 2004-05-05 AU AU2004235848A patent/AU2004235848B2/en not_active Ceased
- 2004-05-05 CN CNB2004800194730A patent/CN100457776C/zh not_active Expired - Fee Related
- 2004-05-07 US US10/842,046 patent/US7386398B2/en active Active
-
2005
- 2005-11-07 IL IL171800A patent/IL171800A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US7386398B2 (en) | 2008-06-10 |
CN1820022A (zh) | 2006-08-16 |
JP4584909B2 (ja) | 2010-11-24 |
CA2522574A1 (en) | 2004-11-18 |
CA2522574C (en) | 2015-07-07 |
AU2004235848A1 (en) | 2004-11-18 |
IL171800A (en) | 2013-06-27 |
KR101164070B1 (ko) | 2012-07-12 |
EP1625154A1 (en) | 2006-02-15 |
WO2004099241A1 (en) | 2004-11-18 |
CN100457776C (zh) | 2009-02-04 |
US20050003348A1 (en) | 2005-01-06 |
KR20060011861A (ko) | 2006-02-03 |
EP1625154B1 (en) | 2014-01-08 |
ES2456702T3 (es) | 2014-04-23 |
DK1625154T3 (da) | 2014-02-24 |
JP2007534292A (ja) | 2007-11-29 |
AU2004235848B2 (en) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05012101A (es) | Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. | |
WO2004014852A3 (en) | Iminothiazolidinones as inhibitors of hcv replication | |
TW200518746A (en) | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease | |
EP1771454A4 (en) | PEPTIDE ANALOGUE AS HEPATITIS C HEMMER | |
TW200615275A (en) | Hepatitis C inhibitor dipeptide analogs | |
UA86962C2 (en) | Viral polymerase inhibitors | |
MY140680A (en) | Hepatitis c virus inhibitors | |
ATE474827T1 (de) | Hcv-replikationshemmer | |
WO2006086381A3 (en) | Hepatitis c virus inhibitors | |
TW200508220A (en) | Hepatitis C inhibitor compounds | |
DE60319820D1 (de) | Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien | |
DE60111509D1 (de) | Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease | |
ATE542826T1 (de) | Inhibitoren des hepatitis-c-virus | |
TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
NO20044897L (no) | Hepatitt C virus inhibitorer | |
IS7532A (is) | Heterósýklískir súlfónamíð lifrarbólgu C-veirutálmar | |
MX2007000007A (es) | Inhibidores de polimerasa viral. | |
RS67004A (en) | Macrocyclic peptides active against the hepatitis c virus | |
ATE486889T1 (de) | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c | |
WO2007027248A3 (en) | 3', 5' - cyclic nucleoside analogues for treatment of hcv | |
EA200900676A1 (ru) | Ингибиторы вируса гепатита с | |
MX2008001402A (es) | Inhibidores macrociclicos del virus de la hepatitis c. | |
SG155967A1 (en) | Hcv ns3-ns4a protease inhibition | |
WO2007092645A3 (en) | Novel hcv inhibitor combinations and methods | |
WO2005000308A3 (en) | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |